

ForPatients

by Roche

Macular Degeneration Age-Related Macular Degeneration

Study of RO7250284 in Participants With Neovascular Age-Related Macular Degeneration

Trial Status
Recruiting

Trial Runs In
2 Countries

Trial Identifier
NCT04567303 BP41670

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD)

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT04567303 BP41670
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years

Healthy Volunteers
No
